307: Myeloablative Allogeneic Stem Cell Transplantation in 424 Patients using Busulfan and Cyclophosphamide

Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.

OBJECTIVE To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. DESIGN Retrospective study. SETTING Bone marrow transplantation unit at a university hospital, Hong Kong. PATIENTS Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002...

Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.

Ninety-nine patients with acute nonlymphocytic leukemia (ANLL) received HLA-identical bone marrow transplants (BMTs) from sibling donors after preparation with high doses of busulfan and cyclophosphamide. Forty-nine patients were transplanted in first complete remission (CR), and 50 patients were transplanted in second and third CR and early relapse. Fifty-three received one of three regimens c...

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

The optimal stem cell transplantation (SCT) conditioning therapy for relapsed/refractory nonHodgkin lymphoma (NHL) is not clearly defined. In a retrospective analysis, we examined 25 patients with “high risk” relapsed/refractory NHL who received busulfan, cyclophosphamide, and etoposide (Bu/Cy/VP16) conditioning with autologous or allogeneic SCT. The majority of patients had aggressive histolog...

Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.

allogeneic stem cell transplantation outcome in acute lymphoblastic leukemia patients

introduction: despite achievement to complete remission (cr) with current treatments and new multiple chemotherapeutic agents in acute lymphoblastic leukemia (all) patients, the majority of them still relapse during long-term follow-up. the use of post- remission therapy will reduce early relapse in these cases, but the best option is still debatable. patients and methods: in this retrospective...